Movement Alert｜HJ Science-B Falls 8.41% in Regular Trading, Continues Post-IPO Weakness Amid Profitability Concerns

Market Focus

Jun 26

On June 26, HJ Science-B declined 8.41% in regular trading, trading at HK$43.92 per share, with turnover of HK$6.28 million. The stock continues to face selling pressure following its Hong Kong debut on June 23, when it closed down 56.89% from its IPO price of HK$81.80.

The company listed as a clinical-stage biotech under Chapter 18A with no approved products for commercial sale and no revenue from product sales. Despite its Hong Kong public offering being oversubscribed 2,007.6 times, the stock has failed to sustain momentum in secondary market trading. The most advanced pipeline is only in Phase II clinical trials, and the company reported a net loss of approximately RMB 202 million for the year ended December 2024. Net IPO proceeds of approximately HK$1.02 billion are intended primarily for clinical research and development activities.

HJ Science was co-founded by multiple PhDs and is primarily engaged in the research and development of innovative drugs targeting oncology, autoimmune diseases, and metabolic disorders.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1105272165"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1105272165\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1105272165?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 10:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105272165","market":"hk","top_or_hot":-1,"title":"Movement Alert｜HJ Science-B Falls 8.41% in Regular Trading, Continues Post-IPO Weakness Amid Profitability Concerns","media":"Market Focus","content":"<p><p>On June 26, HJ Science-B declined 8.41% in regular trading, trading at HK$43.92 per share, with turnover of HK$6.28 million. The stock continues to face selling pressure following its Hong Kong debut on June 23, when it closed down 56.89% from its IPO price of HK$81.80.</p><p>The company listed as a clinical-stage biotech under Chapter 18A with no approved products for commercial sale and no revenue from product sales. Despite its Hong Kong public offering being oversubscribed 2,007.6 times, the stock has failed to sustain momentum in secondary market trading. The most advanced pipeline is only in Phase II clinical trials, and the company reported a net loss of approximately RMB 202 million for the year ended December 2024. Net IPO proceeds of approximately HK$1.02 billion are intended primarily for clinical research and development activities.</p><p>HJ Science was co-founded by multiple PhDs and is primarily engaged in the research and development of innovative drugs targeting oncology, autoimmune diseases, and metabolic disorders.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HJ Science-B Falls 8.41% in Regular Trading, Continues Post-IPO Weakness Amid Profitability Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HJ Science-B Falls 8.41% in Regular Trading, Continues Post-IPO Weakness Amid Profitability Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-26 10:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 26, HJ Science-B declined 8.41% in regular trading, trading at HK$43.92 per share, with turnover of HK$6.28 million. The stock continues to face selling pressure following its Hong Kong debut on June 23, when it closed down 56.89% from its IPO price of HK$81.80.</p><p>The company listed as a clinical-stage biotech under Chapter 18A with no approved products for commercial sale and no revenue from product sales. Despite its Hong Kong public offering being oversubscribed 2,007.6 times, the stock has failed to sustain momentum in secondary market trading. The most advanced pipeline is only in Phase II clinical trials, and the company reported a net loss of approximately RMB 202 million for the year ended December 2024. Net IPO proceeds of approximately HK$1.02 billion are intended primarily for clinical research and development activities.</p><p>HJ Science was co-founded by multiple PhDs and is primarily engaged in the research and development of innovative drugs targeting oncology, autoimmune diseases, and metabolic disorders.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06132","symbol_name":"华健未来-B","start_time":0,"source_url":"","article_id":"1105272165","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105272165","pubTimestamp":1782439777,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 26, HJ Science-B declined 8.41% in regular trading, trading at HK$43.92 per share, with turnover of HK$6.28 million. The stock continues to face selling pressure following its Hong Kong debut...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06132":"华健未来-B"},"translate_title":"走势提示|HJ Science-B常规交易下跌8.41%，盈利能力担忧延续IPO后疲软","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06132":1},"content_text":"On June 26, HJ Science-B declined 8.41% in regular trading, trading at HK$43.92 per share, with turnover of HK$6.28 million. The stock continues to face selling pressure following its Hong Kong debut on June 23, when it closed down 56.89% from its IPO price of HK$81.80.The company listed as a clinical-stage biotech under Chapter 18A with no approved products for commercial sale and no revenue from product sales. Despite its Hong Kong public offering being oversubscribed 2,007.6 times, the stock has failed to sustain momentum in secondary market trading. The most advanced pipeline is only in Phase II clinical trials, and the company reported a net loss of approximately RMB 202 million for the year ended December 2024. Net IPO proceeds of approximately HK$1.02 billion are intended primarily for clinical research and development activities.HJ Science was co-founded by multiple PhDs and is primarily engaged in the research and development of innovative drugs targeting oncology, autoimmune diseases, and metabolic disorders.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}